Tin tức & Cập nhật
Xem bài viết Tiêu hóa
Xem

Seladelpar extends benefit to PBC patients with compensated liver cirrhosis
An interim analysis of the open-label phase III ASSURE study finds benefit in seladelpar, a novel delpar (a potent and selective PPAR*-delta agonist), for individuals with primary biliary cholangitis (PBC) and compensated liver cirrhosis.

Statins may protect against primary sclerosing cholangitis in IBD patients
Patients with inflammatory bowel disease (IBD) who use statins appear to have a substantially reduced risk of primary sclerosing cholangitis (PSC), as shown in a retrospective study.

Add-on bispecific antibody may alter treatment landscape of G/GEJ cancer
Adding the PD-1/CTLA-4 bispecific antibody cadonilimab to chemotherapy improves overall survival (OS) and progression-free survival (PFS) in individuals with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer, including patients with PD-L1–low tumours, according to the interim results of the phase III COMPASSION-15 trial.





